A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age

Streptococcus pneumoniae causes a considerable disease burden among children in China. Many isolates exhibit antimicrobial resistance but are often serotypes covered by the 13-valent pneumococcal conjugate vaccine (PCV13). Because the approved infant immunization schedule in China allows PCV13 vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Kai, Hu, Yuemei, Pan, Hongxing, Wu, Jingliang, Zhu, Dandan, Young, Mariano M., Luo, Li, Yi, Zhuobiao, Giardina, Peter C., Gruber, William C., Scott, Daniel A., Watson, Wendy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Pneumococcal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408693/
https://www.ncbi.nlm.nih.gov/pubmed/37549923
http://dx.doi.org/10.1080/21645515.2023.2235926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408693/
https://www.ncbi.nlm.nih.gov/pubmed/37549923
http://dx.doi.org/10.1080/21645515.2023.2235926

Ejemplares similares